CCL21作为系统性硬化症相关肺动脉高压的潜在血清生物标志物
该研究在2个独立前瞻性系统性硬化症(SSc)队列(n=326)、特发性肺动脉高压患者(n=12)和健康对照(n=100)中检测血清CCL19/CCL21水平。结果显示高CCL21水平(≥0.4 ng/ml)患者肺动脉高压发生率高于低水平者(33.3% vs 5.3%,P<0.001),多因素分析中CCL21与肺动脉高压(HR 5.1,95%CI 2.39-10.76)及肺动脉高压相关事件(HR 4.7,95%CI 2.12-10.46)相关,高CCL21水平与生存率降低相关(P<0.001)。
要点
- SSc患者血清CCL21水平高于对照,且在肺动脉高压诊断前即升高。
- 高CCL21水平(≥0.4 ng/ml)患者肺动脉高压发生率高于低水平者(33.3% vs 5.3%,P<0.001)。
- CCL21与肺动脉高压(HR 5.1,95%CI 2.39-10.76)及肺动脉高压相关事件(HR 4.7,95%CI 2.12-10.46)相关。
核心结论
- CCL21似乎是预测SSc相关肺动脉高压风险及肺动脉高压进展的有前景的标志物。
- CCL21可能参与与SSc肺血管损伤发生相关的免疫通路失调。
研究设计与样本
- 研究分析了2个独立前瞻性SSc队列(n=326)、特发性肺动脉高压患者(n=12)和健康对照(n=100)的血清样本。
- 采用酶联免疫吸附测定检测CCL19/CCL21水平,以对照均值+2SD为 cutoff 定义高/低水平。
- 进行了肺动脉高压诊断时的危险分层和肺动脉高压相关事件分析,采用描述性和Cox回归分析。
主要发现
- SSc患者CCL21水平高于对照,且在肺动脉高压诊断前即升高。
- 高CCL21水平(≥0.4 ng/ml)患者肺动脉高压发生率高于低水平者(33.3% vs 5.3%,P<0.001)。
- 多因素分析中CCL21与肺动脉高压相关(HR 5.1,95%CI 2.39-10.76,P<0.001)。
- 多因素分析中CCL21与肺动脉高压相关事件相关(HR 4.7,95%CI 2.12-10.46,P<0.001)。
- 仅诊断时危险分层不能预测肺动脉高压相关事件,但与CCL21水平联合时有显著预测效果(HR 1.3,95%CI 1.03-1.60,P=0.027)。
关键数值与推荐
- 高CCL21水平定义为≥0.4 ng/ml。
- 高CCL21水平患者肺动脉高压发生率33.3%,低水平者5.3%(P<0.001)。
- CCL21与肺动脉高压的HR为5.1(95%CI 2.39-10.76,P<0.001)。
- CCL21与肺动脉高压相关事件的HR为4.7(95%CI 2.12-10.46,P<0.001)。
- 危险分层联合CCL21水平预测肺动脉高压相关事件的HR为1.3(95%CI 1.03-1.60,P=0.027)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Systemic sclerosis (SSc) is a major cause of pulmonary arterial hypertension (PAH). Murine models indicate key roles for chemokines CCL19 and CCL21 and their receptor CCR7 in lung inflammation leading to PAH. The objective of this study was to assess the chemokine CCL19-CCL21 axis in patients with SSc-related PAH. METHODS: Serum samples obtained from 2 independent prospective SSc cohorts (n = 326), patients with idiopathic PAH (n = 12), and healthy control subjects (n = 100) were analyzed for CCL19/CCL21 levels, by enzyme-linked immunosorbent assay. The levels were defined as either high or low, using the mean + 2 SD value in controls as the cutoff value. Risk stratification at the time of PAH diagnosis and PAH-related events were performed. Descriptive and Cox regression analyses were conducted. RESULTS: CCL21 levels were higher in patients with SSc compared with controls and were elevated prior to the diagnosis of PAH. PAH was more frequent in patients with high CCL21 levels (≥0.4 ng/ml) than in those with low CCL21 levels (33.3% versus 5.3% [P < 0.001]). In multivariate analyses, CCL21 was associated with PAH (hazard ratio [HR] 5.1, 95% CI 2.39-10.76 [P < 0.001]) and occurrence of PAH-related events (HR 4.7, 95% CI 2.12-10.46, P < 0.001). Risk stratification at the time of PAH diagnosis alone did not predict PAH-related events. However, when risk at diagnosis was combined with high or low CCL21 level, there was a significant predictive effect (HR 1.3, 95% CI 1.03-1.60 [P = 0.027]). A high CCL21 level was associated with decreased survival (P < 0.001). CONCLUSION: CCL21 appears to be a promising marker for predicting the risk of SSc-related PAH and PAH progression. CCL21 may be part of a dysregulated immune pathway linked to the development of lung vascular damage in SSc.
引用
- Hoffmann-Vold AM, Hesselstrand R, Fretheim H, et al. CCL21 as a Potential Serum Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis. Arthritis Rheumatol. 2018. PMID: 29687634. doi:10.1002/art.40534
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。